Snapshot from Jun 08, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / GenesisCare, SeeTreat Partner for Cancer Care
Business collaboration agreement

GenesisCare, SeeTreat Partner for Cancer Care

Analysis based on 6 articles · First reported May 14, 2026 · Last updated May 14, 2026

Sentiment
60
Attention
3
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between GenesisCare and SeeTree is expected to positively impact the healthcare and medical technology markets by advancing cancer treatment accessibility and efficiency in Australia. This partnership could lead to increased adoption of adaptive radiotherapy technologies, benefiting both companies and potentially influencing other healthcare providers to invest in similar solutions.

Healthcare Medical Technology
Event Summary

GenesisCare, a leading Australian cancer care provider, is collaborating with SeeTree, a software medical device company, to implement SeeTree's ART.1 software across more than 40 radiation oncology centers in Australia starting July 2026. This partnership aims to enhance adaptive radiotherapy, making it more accessible for cancer patients by automating treatment assessment and optimising treatment plans. The ART.1 software has shown significant potential benefits in a multidisciplinary study involving head and neck, breast, and prostate cancer patients, improving accuracy, efficiency, and patient outcomes. Dr. Marcus Dreosti of GenesisCare and Dr. Trang Nguyen of SeeTree both expressed enthusiasm for the collaboration, highlighting its patient-centric approach and innovative potential.

Key Actions
100 GenesisCare collaborated with SeeTree
95 SeeTree rolled out software GenesisCare
Entities Involved
priv
GenesisCare
GenesisCare, a leading Australian cancer care provider, is collaborating with SeeTree to implement ART.1 software, enhancing its adaptive radiotherapy services across Australia.
Importance 90 Sentiment 70
oth
SeeTree
SeeTree, a software medical device company, is partnering with GenesisCare to roll out its ART.1 software, expanding its global presence and impact in cancer treatment.
Importance 90 Sentiment 70
cnt
Australia
Australia is the primary location for the rollout of SeeTree's ART.1 software by GenesisCare, impacting cancer care across more than 40 radiation oncology centers.
Importance 50 Sentiment 20
per
Trang Nguyen
Dr. Trang Nguyen is the CEO and Founder of SeeTree, expressing pride in the collaboration with GenesisCare.
Importance 40 Sentiment 50
per
Marcus Dreosti
Dr. Marcus Dreosti, Chief Medical Officer of GenesisCare, highlights the benefits of the collaboration with SeeTree in making adaptive radiotherapy more accessible.
Importance 40 Sentiment 50
per
Melanie Jackson
Dr. Melanie Jackson, a Radiation Oncologist, provides positive feedback on the ease of use and benefits of SeeTree's ART.1 software.
Importance 30 Sentiment 50
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.